Increases but pronounced state-level disparities in semaglutide prescribing to Medicaid patients from 2018 to 2022.

Examination of the geographic distribution of semaglutide prescriptions across the United States Medicaid program found marked state-level variations highlight potential barriers to access despite the drug's growing clinical importance.